{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:49:33Z","timestamp":1787647773780,"version":"build-2736575974"},"reference-count":34,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2008,7,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The management of recurrent ovarian cancer remains controversial. Single-agent topotecan is an established treatment option, and preliminary evidence suggests improved tumor control by combining topotecan with etoposide or gemcitabine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      Women with relapsed ovarian cancer after primary surgery and platinum-based chemotherapy were randomly assigned to topotecan monotherapy 1.25 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \/d, topotecan 1.0 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      plus oral etoposide 50 mg\/d, or topotecan 0.5 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \/d plus gemcitabine 800 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      on day 1 and 600 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      on day 8 every 3 weeks. Patients were stratified for platinum-refractory and platinum-sensitive disease according to a recurrence-free interval of less or more than 12 months, respectively. The primary end point was overall survival. Secondary end points included progression-free survival, objective response rates, toxicity, and quality of life (as measured by the European Organisation for Research and Treatment of Cancer [EORTC] 30-item Quality-of-Life Questionnaire).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The trial enrolled 502 patients with a mean age of 60.5 years (\u00b1 10.2 years), 208 of whom were platinum resistant. Median overall survival was 17.2 months (95% CI, 13.5 to 21.9 months) with topotecan, 17.8 months (95% CI, 13.7 to 20.0 months) with topotecan plus etoposide (log-rank P = .7647), and 15.2 months (95% CI, 11.3 to 20.9 months) with topotecan plus gemcitabine (log-rank P = .2344). Platinum-sensitive patients lived significantly longer than platinum-refractory patients (21.9 v 10.6 months). The median progression-free survival was 7.0, 7.8, and 6.3 months, respectively. Objective response rates were 27.8%, 36.1%, and 31.6%, respectively. Patients under combined treatment were at higher risk of severe thrombocytopenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Nonplatinum topotecan combinations do not provide a survival advantage over topotecan alone in women with relapsed ovarian cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2007.15.1258","type":"journal-article","created":{"date-parts":[[2008,6,30]],"date-time":"2008-06-30T18:43:32Z","timestamp":1214851412000},"page":"3176-3182","source":"Crossref","is-referenced-by-count":116,"title":["Nonplatinum Topotecan Combinations Versus Topotecan Alone for Recurrent Ovarian Cancer: Results of a Phase III Study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group"],"prefix":"10.1200","volume":"26","author":[{"given":"Jalid","family":"Sehouli","sequence":"first","affiliation":[{"name":"From the Department of Gynecology, Charit\u00e9 University Medical Center; The Center for Clinical Research, Unfallkrankenhaus; Helios-Klinikum Berlin, Germany; Praxis for Gynecologic Oncology, Berlin; Ernst-Moritz-Arndt University of Greifswald, Greifswald; University of Jena, Jena; Ludwig-Maximilian-Universit\u00e4t of Munich, Munich; Klinikum Ernst-von-Bergmann Potsdam, Potsdam; Practice for Oncology and Hematology, Kronach, Germany; and the University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Stengel","sequence":"additional","affiliation":[{"name":"From the Department of Gynecology, Charit\u00e9 University Medical Center; The Center for Clinical Research, Unfallkrankenhaus; Helios-Klinikum Berlin, Germany; Praxis for Gynecologic Oncology, Berlin; Ernst-Moritz-Arndt University of Greifswald, Greifswald; University of Jena, Jena; Ludwig-Maximilian-Universit\u00e4t of Munich, Munich; Klinikum Ernst-von-Bergmann Potsdam, Potsdam; Practice for Oncology and Hematology, Kronach, Germany; and the University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guelten","family":"Oskay-Oezcelik","sequence":"additional","affiliation":[{"name":"From the Department of Gynecology, Charit\u00e9 University Medical Center; The Center for Clinical Research, Unfallkrankenhaus; Helios-Klinikum Berlin, Germany; Praxis for Gynecologic Oncology, Berlin; Ernst-Moritz-Arndt University of Greifswald, Greifswald; University of Jena, Jena; Ludwig-Maximilian-Universit\u00e4t of Munich, Munich; Klinikum Ernst-von-Bergmann Potsdam, Potsdam; Practice for Oncology and Hematology, Kronach, Germany; and the University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain G.","family":"Zeimet","sequence":"additional","affiliation":[{"name":"From the Department of Gynecology, Charit\u00e9 University Medical Center; The Center for Clinical Research, Unfallkrankenhaus; Helios-Klinikum Berlin, Germany; Praxis for Gynecologic Oncology, Berlin; Ernst-Moritz-Arndt University of Greifswald, Greifswald; University of Jena, Jena; Ludwig-Maximilian-Universit\u00e4t of Munich, Munich; Klinikum Ernst-von-Bergmann Potsdam, Potsdam; Practice for Oncology and Hematology, Kronach, Germany; and the University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Sommer","sequence":"additional","affiliation":[{"name":"From the Department of Gynecology, Charit\u00e9 University Medical Center; The Center for Clinical Research, Unfallkrankenhaus; Helios-Klinikum Berlin, Germany; Praxis for Gynecologic Oncology, Berlin; Ernst-Moritz-Arndt University of Greifswald, Greifswald; University of Jena, Jena; Ludwig-Maximilian-Universit\u00e4t of Munich, Munich; Klinikum Ernst-von-Bergmann Potsdam, Potsdam; Practice for Oncology and Hematology, Kronach, Germany; and the University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Klare","sequence":"additional","affiliation":[{"name":"From the Department of Gynecology, Charit\u00e9 University Medical Center; The Center for Clinical Research, Unfallkrankenhaus; Helios-Klinikum Berlin, Germany; Praxis for Gynecologic Oncology, Berlin; Ernst-Moritz-Arndt University of Greifswald, Greifswald; University of Jena, Jena; Ludwig-Maximilian-Universit\u00e4t of Munich, Munich; Klinikum Ernst-von-Bergmann Potsdam, Potsdam; Practice for Oncology and Hematology, Kronach, Germany; and the University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Stauch","sequence":"additional","affiliation":[{"name":"From the Department of Gynecology, Charit\u00e9 University Medical Center; The Center for Clinical Research, Unfallkrankenhaus; Helios-Klinikum Berlin, Germany; Praxis for Gynecologic Oncology, Berlin; Ernst-Moritz-Arndt University of Greifswald, Greifswald; University of Jena, Jena; Ludwig-Maximilian-Universit\u00e4t of Munich, Munich; Klinikum Ernst-von-Bergmann Potsdam, Potsdam; Practice for Oncology and Hematology, Kronach, Germany; and the University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Paulenz","sequence":"additional","affiliation":[{"name":"From the Department of Gynecology, Charit\u00e9 University Medical Center; The Center for Clinical Research, Unfallkrankenhaus; Helios-Klinikum Berlin, Germany; Praxis for Gynecologic Oncology, Berlin; Ernst-Moritz-Arndt University of Greifswald, Greifswald; University of Jena, Jena; Ludwig-Maximilian-Universit\u00e4t of Munich, Munich; Klinikum Ernst-von-Bergmann Potsdam, Potsdam; Practice for Oncology and Hematology, Kronach, Germany; and the University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oumar","family":"Camara","sequence":"additional","affiliation":[{"name":"From the Department of Gynecology, Charit\u00e9 University Medical Center; The Center for Clinical Research, Unfallkrankenhaus; Helios-Klinikum Berlin, Germany; Praxis for Gynecologic Oncology, Berlin; Ernst-Moritz-Arndt University of Greifswald, Greifswald; University of Jena, Jena; Ludwig-Maximilian-Universit\u00e4t of Munich, Munich; Klinikum Ernst-von-Bergmann Potsdam, Potsdam; Practice for Oncology and Hematology, Kronach, Germany; and the University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Keil","sequence":"additional","affiliation":[{"name":"From the Department of Gynecology, Charit\u00e9 University Medical Center; The Center for Clinical Research, Unfallkrankenhaus; Helios-Klinikum Berlin, Germany; Praxis for Gynecologic Oncology, Berlin; Ernst-Moritz-Arndt University of Greifswald, Greifswald; University of Jena, Jena; Ludwig-Maximilian-Universit\u00e4t of Munich, Munich; Klinikum Ernst-von-Bergmann Potsdam, Potsdam; Practice for Oncology and Hematology, Kronach, Germany; and the University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Lichtenegger","sequence":"additional","affiliation":[{"name":"From the Department of Gynecology, Charit\u00e9 University Medical Center; The Center for Clinical Research, Unfallkrankenhaus; Helios-Klinikum Berlin, Germany; Praxis for Gynecologic Oncology, Berlin; Ernst-Moritz-Arndt University of Greifswald, Greifswald; University of Jena, Jena; Ludwig-Maximilian-Universit\u00e4t of Munich, Munich; Klinikum Ernst-von-Bergmann Potsdam, Potsdam; Practice for Oncology and Hematology, Kronach, Germany; and the University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2006.03.004"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.57.1.43"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041842"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-200032761"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Main C, Bojke L, Griffin S, et al: Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: A systematic review and economic evaluation. Health Technol Assess 10:1,2006-148,","DOI":"10.3310\/hta10090"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2007.04.004"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Bookman MA: Extending the platinum-free interval in recurrent ovarian cancer: The role of topotecan in second-line chemotherapy. Oncologist 4:87,1999-94,","DOI":"10.1634\/theoncologist.4-2-87"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-2-186"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-9-686"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.12.3056"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2183"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.7.1893"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.11.734"},{"key":"R14","unstructured":"Ganem G, Gladieff L, Guastalla JP, et al: Sequential topotecan and etoposide in pretreated ovarian cancer patients: A GINECO phase II study. Proc Am Soc Clin Oncol 17:355a,1998,  (abstr 1371)"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj979"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008364327684"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3345"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1989.132"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1046\/j.1341-8076.2003.00087.x"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf294"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.2307\/2530299"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi147"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2004.07.011"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.0913"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13718-X"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Armstrong DK: Topotecan dosing guidelines in ovarian cancer: Reduction and management of hematologic toxicity. Oncologist 9:33,2004-42,","DOI":"10.1634\/theoncologist.9-1-33"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.14.3312"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(90)90174-J"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.3.389"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2006.03.012"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1232"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Sehouli J, Oskay G, Stengel D, et al: Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer (TOWER): A randomized, two-stage phase-II study of the North-Eastern German Society of Gynaecological Oncology (NOGGO). J Clin Oncol 25:280s,2007,  (suppl; abstr 5526)","DOI":"10.1200\/jco.2007.25.18_suppl.5526"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2007.15.1258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T16:16:58Z","timestamp":1653495418000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2007.15.1258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,1]]},"references-count":34,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2008,7,1]]}},"alternative-id":["10.1200\/JCO.2007.15.1258"],"URL":"https:\/\/doi.org\/10.1200\/jco.2007.15.1258","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,1]]}}}